...
首页> 外文期刊>Canadian journal of gastroenterology & hepatology. >Increased eligibility for treatment of chronic hepatitis C infection with shortened duration of therapy: Implications for access to care and elimination strategies in Canada
【24h】

Increased eligibility for treatment of chronic hepatitis C infection with shortened duration of therapy: Implications for access to care and elimination strategies in Canada

机译:缩短治疗持续时间的治疗慢性丙型肝炎感染的资格增加:加拿大在加拿大的护理和消除策略的启示

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: All oral, highly effective direct-acting antiviral combinations, such as sofosbuvir-ledipasvir, have recently been licensed in Canada but cost as much as $67,000 for a 12-week course of therapy, representing a major economic barrier to predominately single-payer health care systems such as that found in Ontario. In hepatitis C virus (HCV) genotype 1 noncirrhotic patients with a baseline viral load of = 95% efficacy. The number of HCV-infected patients in Ontario eligible for shortened therapy, and the associated cost savings, are unknown. The authors propose that treating every patient with shortened therapy, regardless of baseline viral load, would lead to significant public cost savings and collateral efficiencies, enabling increased HCV treatment capacity and cure.
机译:背景:所有口头,高效的直接抗病毒素组合,如Sofosbuvir-Ledipasvir,最近在加拿大获得了许可,但为期12周的治疗课程的费用高达67,000美元,代表主要经济障碍的主要经济障碍 在安大略省发现的医疗保健系统。 在丙型肝炎病毒(HCV)基因型1个非抑弹患者的基线病毒载量= 95%的疗效。 有资格缩短治疗的安大略省的HCV感染患者以及相关成本节省的患者的数量未知。 作者提出,无论基线病毒载量如何,治疗治疗的每只患者都会导致大量的公共成本节约和抵押效率,从而提高HCV治疗能力和治愈。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号